Loading...
Loading...
LMNL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 7.9M |
| Operating I/L | -10.4M |
| Other Income/Expense | 5.9M |
| Interest Income | 1.0M |
| Pretax | -4.5M |
| Income Tax Expense | -33.2M |
| Net Income/Loss | 21.9M |
Liminal BioSciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases. The company's lead product candidate, fezagepras (PBI-4050), has completed Phase I clinical trials for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis and respiratory diseases. Additionally, Liminal BioSciences Inc. is developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in the preclinical stage.
